# US 10,118,938 B2 · Arsenoplatin anti-cancer agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,118,938 B2
- Document ID: US10118938B2
- Status: Granted
- Kind: B2
- Application number: 15/637,179
- Filed: 2017-06-29
- Published: 2017-12-14
- Granted: 2018-11-06
- Earliest claimed: 2012-08-14
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Denana U. Miodragovic; Thomas V. O'Halloran
- Web page: https://patentgrep.com/patent/US10118938B2

## CPC

- C07F 15/0013: {without a metal-carbon linkage}
- A61K 31/282: Platinum compounds
- A61K 31/285: Arsenic compounds
- A61K 31/29: Antimony or bismuth compounds
- A61K 31/295: Iron group metal compounds
- A61P 35/00: Antineoplastic agents
- C07F 15/0066: {without a metal-carbon linkage}
- C07F 15/0093: {without a metal-carbon linkage}
- C07F 15/045: {without a metal-carbon linkage}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods of treating a cancer cell that include contacting a cancer cell with a compound having the structure of formula (I) M is Pt, Pd or Ni; Q is As, Sb or Bi; Z1 is N; Z2 is O or S; L1 and L2 are independently C(O), C—R1 or C—R2; X is a Lewis base; Y1 and Y2 are independently selected from —OR3, —OR4, —SR3 and —SR4, wherein R1 and R2 are independently selected from hydrogen, halogen, cyano, keto, ester, ether, thiol, thioether, thioester, imino, C1-C10 alkyl, C1-C10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C3-C15 cycloalkyl, heteroaryl, and C3-C15 heterocycloalkyl; and R3 and R4 are independently selected from hydrogen, C1-C10 alkyl, C1-C10 alkenyl, alkynyl, alkoxyl, amino, amidyl, immino, sulfonyl, sulfoxyl, phosphoryl, phosphoryl ester, glycosyl, aryl, C3-C15 cycloalkyl, heteroaryl, and C3-C15 heterocycloalkyl.

## Claims

### Claim 1

A method of treating a human cancer cell, comprising:
contacting the human cancer cell with an effective amount of a compound selected from the group consisting of compounds (1)-(19):
wherein the human cancer cell is selected from the group of cancers consisting of triple negative breast cancer, ovarian cisplatin resistant cancer, multiple myeloma, glioblastoma and colon cancer.

### Claim 2

A method of treating a human cancer cell, comprising:
contacting the human cancer cell with an effective amount of compound (1):
wherein the human cancer cell is selected from the group of cancers consisting of triple negative breast cancer, ovarian cisplatin resistant cancer, multiple myeloma, glioblastoma and colon cancer.